GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Cyclically Adjusted PS Ratio

Kamada (XTAE:KMDA) Cyclically Adjusted PS Ratio : 1.70 (As of May. 24, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Kamada Cyclically Adjusted PS Ratio?

As of today (2024-05-24), Kamada's current share price is ₪19.17. Kamada's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₪11.30. Kamada's Cyclically Adjusted PS Ratio for today is 1.70.

The historical rank and industry rank for Kamada's Cyclically Adjusted PS Ratio or its related term are showing as below:

XTAE:KMDA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.29   Med: 1.78   Max: 2.47
Current: 1.7

During the past years, Kamada's highest Cyclically Adjusted PS Ratio was 2.47. The lowest was 1.29. And the median was 1.78.

XTAE:KMDA's Cyclically Adjusted PS Ratio is ranked better than
58.06% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.115 vs XTAE:KMDA: 1.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kamada's adjusted revenue per share data for the three months ended in Mar. 2024 was ₪2.343. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₪11.30 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kamada Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Kamada's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Cyclically Adjusted PS Ratio Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.18 2.05 1.29 2.02

Kamada Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 1.78 1.85 2.02 1.82

Competitive Comparison of Kamada's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kamada's Cyclically Adjusted PS Ratio falls into.



Kamada Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kamada's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=19.17/11.3
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kamada's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Kamada's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.343/131.7762*131.7762
=2.343

Current CPI (Mar. 2024) = 131.7762.

Kamada Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.595 100.560 2.090
201409 1.956 100.428 2.567
201412 2.367 99.070 3.148
201503 0.929 99.621 1.229
201506 1.810 100.684 2.369
201509 1.659 100.392 2.178
201512 2.558 99.792 3.378
201603 1.418 100.470 1.860
201606 1.766 101.688 2.289
201609 2.050 101.861 2.652
201612 2.219 101.863 2.871
201703 1.183 102.862 1.516
201706 3.195 103.349 4.074
201709 2.090 104.136 2.645
201712 2.391 104.011 3.029
201803 1.529 105.290 1.914
201806 3.059 106.317 3.792
201809 1.380 106.507 1.707
201812 4.699 105.998 5.842
201903 2.398 107.251 2.946
201906 3.160 108.070 3.853
201909 2.918 108.329 3.550
201912 2.824 108.420 3.432
202003 2.810 108.902 3.400
202006 3.513 108.767 4.256
202009 2.846 109.815 3.415
202012 2.550 109.897 3.058
202103 2.041 111.754 2.407
202106 1.899 114.631 2.183
202109 2.001 115.734 2.278
202112 2.841 117.630 3.183
202203 2.257 121.301 2.452
202206 1.988 125.017 2.095
202209 2.444 125.227 2.572
202212 3.490 125.222 3.673
202303 2.493 127.348 2.580
202306 3.034 128.729 3.106
202309 2.592 129.860 2.630
202312 2.344 129.419 2.387
202403 2.343 131.776 2.343

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kamada  (XTAE:KMDA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kamada Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Kamada's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada (XTAE:KMDA) Business Description

Industry
Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada (XTAE:KMDA) Headlines

From GuruFocus

Kamada Announces Planned Transition of Chief Financial Officer

By Value_Insider Value_Insider 12-19-2022

Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference

By Value_Insider Value_Insider 10-26-2022